CN1634249A - Chinese medicinal composition for treating hemorrhagic brain contusion and laceration - Google Patents

Chinese medicinal composition for treating hemorrhagic brain contusion and laceration Download PDF

Info

Publication number
CN1634249A
CN1634249A CN200410040823.3A CN200410040823A CN1634249A CN 1634249 A CN1634249 A CN 1634249A CN 200410040823 A CN200410040823 A CN 200410040823A CN 1634249 A CN1634249 A CN 1634249A
Authority
CN
China
Prior art keywords
group
radix
laceration
brain
blood
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN200410040823.3A
Other languages
Chinese (zh)
Other versions
CN100446791C (en
Inventor
王宪荣
洪多伦
冯华
朱刚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Affiliated Hospital of TMMU
Original Assignee
First Affiliated Hospital of TMMU
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Affiliated Hospital of TMMU filed Critical First Affiliated Hospital of TMMU
Priority to CNB2004100408233A priority Critical patent/CN100446791C/en
Publication of CN1634249A publication Critical patent/CN1634249A/en
Application granted granted Critical
Publication of CN100446791C publication Critical patent/CN100446791C/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)

Abstract

The invention discloses a Chinese medicinal composition for treating hemorrhagic brain contusion and laceration, which is prepared from ten Chinese medicinal herbs including peach kernels, safflower, Ligusticum wallichii, Chinese angelica root, dried rehmannia root, poria cocos wolf. The composition can be prepared into any of the pharmacologically acceptable dosage forms.

Description

A kind of Chinese medicine composition for the treatment of hemorrhagic contusion and laceration of brain
Technical field
The present invention relates to a kind of medicine for the treatment of hemorrhagic contusion and laceration of brain, specifically be a kind of be the Chinese patent medicine of feedstock production with Chinese medicine.
Technical background
Hemorrhagic contusion and laceration of brain is modal one of type of hindering in the craniocerebral trauma, accounts for the 20%--40% of craniocerebral trauma.Its main pathological lesion is cerebral tissue fragmentation, necrosis, hemorrhage, edema and cerebral microvascular thromboembolism.These pathological lesions not only can directly cause delayed ischemic neurological deficits, secondary intracranial pressure rising threat to life, and be to cause brain injury kitchen range and surrounding tissue to carry out the major reason of ischemia, anoxia, acidosis and brain cell degeneration necrosis, influence traumatic condition and lapse to life quality with the wounded.Doctor trained in Western medicine mainly is to use medicines such as dehydration, hemostasis and hormones to treatment light, medium-sized hemorrhagic contusion and laceration of brain, though certain curative effect is arranged, but it is still not ideal enough, and more side effect is arranged, can cause Water-Electrolyte disorder and renal function injury as dehydrant mannitol, hormone can cause hyperglycemia, digestive tract hemorrhage, reduces Abwehrkraft des Koepers, increase wound infection, hemorrhage can cause wound hindbrain ischemic lesions.
The content of invention
Technical problem to be solved by this invention provides a kind of treatment by Chinese herbs oral formulations activating blood and removing stasis and QI invigorating eliminating dampness by diuresis effect, that hemorrhagic contusion and laceration of brain had obvious curative effects that has.
The technical solution used in the present invention is based on tcm theory.Theory of Chinese medical science is thought: " blood vessels are obstructed, and QI and blood is become silted up and hindered "." the capable then blood of gas is capable, gas end then blood ends "." blood circulating out of vessels is all the stasis of blood ".The brain inner blood smoulders or congestion stops up, and is all syndrome of blood stasis, and blood-vessel obstructive causes the stasis of QI and blood phlegm-damp and stops amassing, and influences spleen, lung, three organ function imbalances of kidney simultaneously, satisfies and gives birth to phlegm-damp, and the expectorant heresy is disturbed the heart and caused cerebral edema.Hemorrhagic contusion and laceration of brain, intracerebral hematoma and hypertensive cerebral hemorrhage etc. belong to this card, and method of treatment palpus activating blood and removing stasis and the same usefulness of QI invigorating eliminating dampness by diuresis have Semen Persicae, Flos Carthami and Rhizoma Chuanxiong etc. as the activating blood and removing stasis medicine, and the invigorating vital QI medicine has the Radix Astragali, Radix Glycyrrhizae etc., and damp-clearing drug has Poria etc.
According to above-mentioned theory, medicine of the present invention is made by the following components by weight parts proportioning:
Semen Persicae 4-10 Flos Carthami 3-10 Rhizoma Chuanxiong 3-10
Radix Paeoniae Rubra 6-12 Radix Angelicae Sinensis 4-10 Radix Rehmanniae 9-15
Poria 9-15 Radix Astragali 9-30 Radix Angelicae Dahuricae 3-10
Radix Glycyrrhizae 1-9
In aforementioned pharmaceutical compositions, Semen Persicae, Flos Carthami, Rhizoma Chuanxiong, Radix Paeoniae Rubra activating blood and removing stasis, wind-expelling pain-stopping are monarch drug; Radix Rehmanniae heat clearing and blood cooling is equipped with the Radix Angelicae Sinensis nourishing blood and promoting blood circulation and moisturizes, and makes blood stasis dispelling and non-impairment of YIN blood is ministerial drug; Radix Angelicae Dahuricae anti-inflammatory analgetic, priming is up, the Poria promoting diuresis to eliminate damp pathogen, and Radix Astragali QI invigorating diuretic is an adjuvant drug, Radix Astragali QI invigorating diuretic, the capable then blood of gas is capable, not only strengthens the effect of blood stasis dispelling, and uses the effect that can also strengthen the QI invigorating diuretic together with Poria, make diuretic and do not hinder healthy energy, help the absorption of cerebral edema, strengthen the brain cell hypoxia-bearing capability, alleviate the cerebral tissue secondary lesion; Radix Glycyrrhizae invigorating the spleen and replenishing QI, coordinating the actions of various ingredients in a prescription are messenger drug.The synergism of each component and produce activating blood and removing stasis, the effect of QI invigorating eliminating dampness by diuresis is the double medicine of controlling of blood stasis and edema.In addition, the medical material avirulence medical material of compatibility, incompatibilitys such as no eighteen incompatible medicaments, nineteen medicaments of mutual restraint.
The specific embodiment
1, the preferred weight portion ratio range of preparation medicine of the present invention is:
Semen Persicae 6-9 Flos Carthami 5-9 Rhizoma Chuanxiong 5-9
Radix Paeoniae Rubra 7-12 Radix Angelicae Sinensis 6-9 Radix Rehmanniae 11-15
Poria 10-14 Radix Astragali 12-25 Radix Angelicae Dahuricae 5-9
Radix Glycyrrhizae 5-7
2, optimum weight part proportioning of medicine of the present invention is:
Semen Persicae 10 Flos Carthamis 10 Rhizoma Chuanxiongs 10
Radix Paeoniae Rubra 12 Radix Angelicae Sinensis 10 Radix Rehmanniae 12
Poria 12 Radixs Astragali 12 Radixs Angelicae Dahuricae 10
Radix Glycyrrhizae 5
3, preparation technology and usage
(1), take by weighing medical material, put that water cleans twice in the bulk container, move in the multi-function extractor water and carry by proportion relation; 10 times of water gagings that add medical material weight for the 1st time decocted 1 hour, add 8 times of water gagings the 2nd, 3 time to decoct 40 minutes, and filter cleaner, merging filtrate is condensed into the clear paste (temperature is 70 ℃ in jar) of 1: 1 ratio with thin film concentrator; Clear paste is put and is left standstill cooling at least 16 hours in the container; Get supernatant and filter, remove precipitate, be condensed into the thick paste (interior temperature 60--70 ℃ of jar) of 1.38-1.40 proportion with the vacuum decompression concentrator with high speed centrifuge; Get 4 parts of thick pastes, 1 part of sucrose, 0.5 part in dextrin is granulated (temperature is 70 ℃ in jar) granulate with airpillow-dry granulator; Granule restrains (amounting to crude drug 24.6 grams) packing with automatic packaging machine by every bag 10 after the assay was approved.
Except above-mentioned preparation technology, can be prepared into the pharmaceutically various peroral dosage forms of acceptable.
(2), this preparation is brown granular, the sweet little hardship of distinguishing the flavor of.Be used for light, medium-sized hemorrhagic contusion and laceration of brain etc.Take after mixing it with hot water, adult every day 3 times, each 1 bag (10 gram), 7-10 day was 1 course of treatment.Be not taken by pregnant women.
4, composition qualitative identification
Use that specificity is strong, highly sensitive, the thin layer chromatography of favorable reproducibility is to carrying out qualitative identification according to main Chinese medicinal materials in three batches of drug particles of above-mentioned explained hereafter, and contrast with positive medical material and negative control (not containing this preparation that will differentiate medical material), obtain the identical table 1 that the results are shown in.
Three batches of this preparation compositions of table 1 qualitative identification
Group Flos Carthami Semen Persicae szechuan lovage rhizome Radix Angelicae Sinensis
This preparation+++++
Positive medical material+++++
Negative control-----
Annotate :+positive, this medical material is promptly arranged;-negative, promptly there is not this medical material.
The result shows that this preparation medicine material component is stable.
5, animal experiment study
(1), this preparation of maximum dosage-feeding experimental evidence theories of Chinese materia medica does not contain the toxicity medical material and clinical practice has no side effect, and judges that this preparation is difficult for measuring LD50, selects the maximum dosage-feeding test.64 of Kunming kind healthy mices (male and female each half) are divided into four groups at random: irritate 10%, 45% and 60% preparation aqueous solution 1ml of stomach 1 time, (dosage is the 5g/kg body weight to be respectively 25 times of groups, be equivalent to be grown up 25 times of 1 dosage are below analogized), 112.5 times of groups (22.5g/kg body weight) and 150 times of groups (30g/kg body weight); Matched group is irritated stomach 0.9% sodium chloride injection 1ml 1 time.Irritated stomach preceding 1 day and back 7 days title mice body weight, observe 7 days mices behind the filling stomach continuously and have or not toxic reaction and death toll.The results are shown in table 2
Body weight and the mortality rate of four groups of mices of table 2
Body weight (g)Mortality rate
Group Mus number
Behind the preceding filling of the filling stomach stomach (%)
Contrast 21 19.4 ± 1.9 21.2 ± 4.7 9.5
25 times 22 18.2 ± 2.0 20.0 ± 3.7 4.5
112.5 doubly 21 18.8 ± 1.8 20.2 ± 4.0 0
150 times 18 22.5 ± 2.6 24.0 ± 3.1 0
Body weight is animal appetite, take food, digest and assimilate and the concentrated expression of substance metabolism, increases equally than average weight before the administration and matched group after all survival mice administrations, shows that this preparation has no adverse effects to these links of mice.No poisoning clinical manifestation, well-known, 0.9% sodium chloride injection avirulence, and drug toxicity usually be directly proportional to medicament, 112.5 and 150 times of groups do not have death as known from Table 2, and death appears in matched group and 25 times of groups on the contrary, and its reason may or be irritated stomach with individual body constitution difference and be caused damaging relevant.
The conclusion mice is to 150 times of 1 dosage of the suitable adult of 1 maximum dosage-feeding of this preparation, (the 30g/Kg body weight is amounted to crude drug 73.8g/Kg), no toxic reaction and death in 7 days, this preparation avirulence is described, consistent with theories of Chinese materia medica and clinical practice result.
(2), the healthy Wistar rat of long term toxicity test is 97 (male 49, female 48) be divided into 4 groups at random, point of accumulation in the time of 3: irritate 10%, 20% and 40% each 2ml of preparation of stomach, every day 2 times, continuous 10 days, be respectively low dose group (L group), middle dosage group (M group) and high dose group (H group), matched group (C group) is only irritated stomach 0.9% sodium chloride injection 2ml, also be every day 2 times, continuous 10 days.Respectively organize rat blood routine and biochemical index with full-automatic medical check analysis instrument and the detection of former installed reagents, carry out general clinical observation, body weight and pathological examination simultaneously.Observe week aspire to irritating for the 1st time behind the stomach the 11st, 21 and 31 day.The result is as follows:
(the comparison of x ± S) of four groups of the 11st day blood routine hepatic and renal function indexs of table 3
C group L group M group H group
Index
(10) (9) (10) (10)
Leukocyte count * 10 9/ L 31.3 ± 15.3 29.2 ± 15.3 25.0 ± 13.6 30.4 ± 12.5
RBC number * 10 12/ L 6.43 ± 1.2 6.68 ± 0.8 6.71 ± 1.0 7.33 ± 0.6
Hemoglobin content g/L 117.4 ± 28.8 121.3 ± 11.5 110.9 ± 19.4 131.0 ± 12.0
Packed cell volume % 39.5 ± 8.7 40.3 ± 3.1 37.9 ± 5.3 43.4 ± 4.0
Platelet count * 10 9/ L 692.5 ± 161.0 593.8 ± 131.2 818.0 ± 303.6 774.9 ± 200.4
Glutamate pyruvate transaminase lu/L 68.2 ± 14.2 73.6 ± 20.0 74.9 ± 27.8 69.9 ± 38.4
Glutamic oxaloacetic transaminase, GOT lu/L 229.5 ± 93.7 218.6 ± 41.6 236.7 ± 87.0 223.2 ± 88.8
Total bilirubin umol/L 1.6 ± 0.6 1.7 ± 0.6 1.3 ± 0.5 1.3 ± 0.6
The plain mmol/L 6.9 of hematuria ± 1.2 6.8 ± 1.3 6.8 ± 2.4 8.8 ± 7.2
Serum creatinine umol/L 47.2 ± 10.7 49.6 ± 9.4 48.1 ± 9.5 49.9 ± 15.0
Total protein g/L 56.8 ± 7.3 59.8 ± 6.7 59.6 ± 5.0 60.6 ± 6.8
Albumin g/L 25.7 ± 3.1 27.5 ± 4.2 25.1 ± 3.2 28.1 ± 4.2
Globulin g/L 31.1 ± 6.2 32.3 ± 5.8 34.5 ± 5.1 32.5 ± 6.0
Archon ratio 0.86 ± 0.2 0.87 ± 0.2 0.75 ± 0.2 0.91 ± 0.3
Blood glucose mmol/L 7.5 ± 2.5 8.6 ± 3.0 7.8 ± 3.3 8.7 ± 1.3
Annotate: 3 administration groups of t check are compared the P value all greater than 0.05 with matched group.
(the comparison of x ± S) of four groups of the 21st day blood routine hepatic and renal function indexs of table 4
C group L group M group H group
Index
(9) (5) (5) (9)
Leukocyte count * 10 9/ L 31.5 ± 7.2 31.3 ± 7.3 29.1 ± 9.8 21.7 ± 4.9 *
RBC number * 10 12/ L 7.48 ± 9.0 7.57 ± 0.5 7.78 ± 1.1 7.55 ± 0.4
Hemoglobin content g/L 129.2 ± 12.2 135.4 ± 8.0 144.2 ± 19.8 134.4 ± 10.4
Packed cell volume % 40.2 ± 3.4 45.0 ± 3.2 *46.6 ± 6.7 *40.7 ± 4.4
Platelet count * 10 9/ L 661.2 ± 317.1 843.6 ± 284.7 888.4 ± 147.5 834.9 ± 239.1
Glutamate pyruvate transaminase lu/L 71.6 ± 17.9 68.0 ± 16.9 58.0 ± 10.4 60.8 ± 23.3
Glutamic oxaloacetic transaminase, GOT lu/L 308.3 ± 226.4 236.8 ± 37.0 231.4 ± 76.8 254.9 ± 76.5
Total bilirubin umol/L 3.7 ± 3.1 3.5 ± 2.0 2.3 ± 0.8 2.1 ± 0.9
The plain mmol/L 7.0 of hematuria ± 1.3 7.9 ± 0.9 6.8 ± 1.0 7.2 ± 1.3
Serum creatinine umol/L 50.7 ± 21.6 68.4 ± 3.4 66.8 ± 11.4 51.7 ± 31.2
Total protein g/L 63.6 ± 10.3 63.8 ± 7.3 61.7 ± 2.6 60.6 ± 5.2
Albumin g/L 29.5 ± 4.6 31.6 ± 3.9 32.5 ± 5.7 32.4 ± 3.2
Globulin g/L 34.1 ± 7.6 32.2 ± 6.6 29.2 ± 3.8 27.6 ± 6.2
Archon ratio 0.89 ± 0.2 1.02 ± 0.2 1.15 ± 0.3 1.23 ± 0.3*
Blood glucose mmol/L 8.1 ± 2.0 7.1 ± 2.1 6.1 ± 1.5 7.9 ± 2.3
Annotate: all high C group of packed cell volume L, M group; H group is compared the low and Archon ratio height of leukocyte count with the C group, 3 administration groups of all the other indexs are compared the P value all greater than 0.05 with matched group
(the comparison of x ± S) of four groups of the 31st day blood routine hepatic and renal function indexs of table 5
C group L group M group H group
Index
(7) (6) (10) (6)
Leukocyte count * 10 9/ L 22.2 ± 7.9 26.1 ± 9.1 29.8 ± 11.5 15.0 ± 11.7
RBC number * 10 12/ L 7.17 ± 0.51 7.0 ± 0.7 7.20 ± 0.68 7.34 ± 0.76
Hemoglobin content g/L 138.6 ± 11.9 130.5 ± 18.5 139.0 ± 12.7 138.2 ± 17.4
Packed cell volume % 43.3 ± 3.5 40.8 ± 3.6 41.4 ± 4.6 42.7 ± 6.0
Platelet count * 10 9/ L 518.6 ± 202.2 552.8 ± 93.8 688.8 ± 212.5 480.3 ± 219.5
Glutamate pyruvate transaminase lu/L 54.8 ± 7.4 57.3 ± 8.1 52.2 ± 8.8 43.2 ± 12.4
Glutamic oxaloacetic transaminase, GOT lu/L 147.4 ± 59.7 128.2 ± 61.1 112.6 ± 16.0 118.2 ± 33.4
Total bilirubin umol/L 1.7 ± 0.7 1.8 ± 0.7 1.6 ± 0.5 1.6 ± 0.2
The plain mmol/L 6.9 of hematuria ± 0.9 6.1 ± 0.6 7.5 ± 1.0 6.7 ± 0.9
Serum creatinine umol/L 54.0 ± 6.0 33.8 ± 11.4 *28.8 ± 10.0 *27.7 ± 12.1 *
Total protein g/L 53.1 ± 4.9 59.8 ± 6.3 56.6 ± 3.8 51.2 ± 10.3
Albumin g/L 28.9 ± 2.3 27.6 ± 2.4 30.2 ± 2.5 25.6 ± 6.2
Globulin g/L 24.2 ± 4.2 32.3 ± 7.9 *26.4 ± 3.8 25.6 ± 7.6
Archon ratio 1.23 ± 0.25 0.91 ± 0.28 1.17 ± 0.21 1.06 ± 0.42
Blood glucose mmol/L 7.5 ± 1.0 7.0 ± 0.8 8.2 ± 1.3 6.4 ± 1.7
Annotate: 3 administration group serum creatinines are starkly lower than matched group, and the L Histaglobin is higher than matched group, and 3 administration groups of all the other indexs are compared the P value all greater than 0.05 with matched group
(the comparison of x ± S) of point of accumulation body weight during four groups three in table 6
Time limit C group L group M group H group
11 days Irritate before the stomach (g) and irritate (g) behind the stomach 174.0±45.1??????164.4±27.3?????171.1±36.6?????182.1±36.2 169.2±38.7??????179.6±38.6?????159.0±31.0?????175.4±39.4
21 days Irritate before the stomach (g) and irritate (g) behind the stomach 243.6±24.6??????260.6±60.2?????287.2±57.2?????293.0±44.1 256.4±29.4??????279.4±52.6?????312.8±80.0?????320.0±56.0
31 days Irritate before the stomach (g) and irritate (g) behind the stomach 227.0±11.8??????215.2±36.9?????213.4±25.6?????235.8±7.9 297.0±55.9*?????276.8±53.3*????274.4±47.3*????271.4±67.4
Annotate: organize weight increase than irritating stomach preceding the 31st day C, L, M after irritating stomach, all the other P values all greater than 0.05,3 administration group each the time point of accumulation when corresponding with matched group point of accumulation to compare the P value also all be greater than 0.05.
This test of clinical meaning of leading indicator is under diet situation the same terms, and body weight reflects the situation of rats eating, digestion, absorption and substance metabolism; Peripheral hemogram can also reflect the hemopoietic tissue function to a certain extent except reflecting situation own; The ability of total protein, albumin and globulin reflection protein metabolism and liver synthetic protein; Paddy third and glutamic oxaloacetic transaminase, GOT raise and reflect that hepatocyte, cardiac muscle and kidney are undermined; Total bilirubin raises, and the disintegrate of reflection red blood cell aging increases or biliary excretion is obstructed; Hematuria element, serum creatinine raise and reflect renal insufficiency; The dysfunction of blood sugar increasing reflection pancreatic secretion insulin.Be lower than the C group (but still at lower limits of normal) except that the 21st day H group of leukocyte count as can be known from table 3-6, this preparation has no adverse effects to exhausted most part index number, shows these histoorgan avirulences.
All activities in rats are normal, impassivity systemic symptom and sign, feed, fur, mucosa and defecate no abnormal.The difference not statistically significant of 3 administration group pathological changes and matched group.
This preparation of conclusion quite is grown up 12.2 times for rat H consumption, and continuous 10 days to non-toxic reactions such as the heart, liver and gall, pancreas, spleen, kidney, lung, hemopoietic tissue, nervous system and substance metabolismes.
6, pharmacodynamic experiment healthy rabbits 68 (body weight 2.5-3.0kg) is divided into two groups at random.The treatment group: preceding 1 week of causing injury is made stomach fistulation pipe art, copies Feeney freely falling body method to cause contusion and laceration of brain, hinders and injects this preparation 8ml/kg/ day through stomach fistulation pipe in back 6 hours, divides 3 times, and continuous 21 days, 1ml contained crude drug 0.4g; Matched group substitutes outside this preparation divided by the isometric(al) normal saline, and all the other conditions are identical with the treatment group.Long-pending with technical measurement brain injury stoves such as graphical analyses, observe pathological changes such as cerebrovascular and blood-brain barrier permeability.Mainly the results are shown in table 7
Table 7 liang group is hindered the comparison of back leading indicator
Time limit Group The brain injury kitchen range Blood vessel blood brain is engulfed the penetrating several first number number property of little barrier cell number nervus vasculairs thrombosis in the little cortex of brain
Water-outlet body hematocele (the mm that swells 3)
7 days The contrast treatment +++??+++??236 +????+????155 ++???+++??-??????+????+ -????+????+++????+++??+++
14 days The contrast treatment +????+????282 -????-????83 -????++???+??????++???++ -????-????+++????+++??+++
Annotate: +++expression severe or volume; ++ expression moderate or middle amount; + represent slight or a small amount of;-expression does not have.
As known from Table 7, all repair with prolonging observing time for two groups, but the treatment group is faster than matched group reparation, the 21st day result also is like this.Show that this preparation can promote the absorption of cerebral hemorrhage and edema, reduce microthrombusis in the blood vessel, improve brain microcirculation, reduce the permeability of blood brain barrier, strengthen phagocytic function, alleviate the neuron secondary lesion, make and hindered the kitchen range healing early 7 days.
7, clinical and experimental study
The acute brain wound wounded 94 examples of Glasgow coma scale (GCS) 6-15 branch (traumatic condition is by heavy extremely light) traumatic condition are divided into two groups by the admission number odevity.The Western medicine group: male's 29 examples, women's 17 examples, totally 46 examples, 36.0 ± 14.3 years old mean age, dewater, doctor trained in Western medicine conventional therapy such as hemostasis and hormone in GCS10.25 ± 2.68 minute.Chinese drug-treated group: male's 28 examples, women's 20 examples, totally 48 examples, 35.2 ± 14.9 years old mean age, GCS10.23 ± 2.70 minute, oral or this preparation of nasal feeding (1ml contains crude drug 0.4g), every day, 4ml/kg divided 3 administrations, and 7 was 1 course of treatment, treatment 1-3 course of treatment.Two groups are all used antibiotic prophylaxis to infect.Cranium brain CT examination is to measure the amount and the edema degree of cerebral hemorrhage; Measure hemorheology index, blood plasma superoxide dismutase activity and lipid peroxidation product content etc.; Hinder and followed up a case by regular visits in back 3 months, the evaluation of GCS final result adopts 5 point-scores to estimate rehabilitation situation.The results are shown in table 8-9.
Table 8 liang the 15th day test rating result's of group comparison
Index (unit) Western medicine group Chinese drug-treated group
The whole blood viscosity height is cut (mPa/s) 5.34 4.65 *
Low (mPa/s) 9.87 9.37 that cut of whole blood viscosity *
Plasma viscosity (mPa/s) 1.56 1.47 *
Erythrocyte is built up index 3.18 2.51 *
Fibrinogen (g/L) 4.71 3.24 *
Packed cell volume (%) 41.4 38.3 *
Superoxide dismutase activity (nu/ml) 80.7 90.8 *
Lipid peroxide contents (umol/ml) ▲ 3.93 3.90
Thromboxance B 2(Pg/L) ▲ 135.2 120.7
Activator of plasminogen (IU/ml) 1.28 1.39 *
Plasminogen mortifier (AU/ml) 9.42 8.27 *
Annotate: * represents to compare P＜0.05 or P＜0.01 with the Western medicine group; The the 3rd, 7 day Chinese drug-treated group of ▲ expression is starkly lower than the Western medicine group.
The check result of table 9 liang group treatment back leading indicator
Group The 15th day3 months
Cephalophyma (ml) the cerebral edema disappearance GCS cure rate (%) of scoring
(％)
Western medicine group 10.7 32.3 12.8 16
Chinese drug-treated group *4.5 56.7 13.8 60
Annotate: the data of all indexs and Western medicine group compared P＜0.05 or P＜0.01 in * represented.
From table 8-9 as can be known, this preparation can promote the absorption of cephalophyma and cerebral edema, alleviates or eliminates clinical symptoms and sign, improves cure rate, and aspects such as reduction disability rate are better than the Western medicine group.This external hemorheology properties of improving is regulated aspects such as body fibrinolytic-coagulation function and lipoid peroxidization resistant and also obviously is better than the doctor trained in Western medicine conventional therapy.
The effect of this preparation for treating of conclusion acute brain traumatic patient is apparently higher than the doctor trained in Western medicine conventional therapy.

Claims (4)

1, a kind of Chinese medicine composition for the treatment of hemorrhagic contusion and laceration of brain is characterized in that the medicament of being made by following weight (part) proportioning by following traditional Chinese medicines:
Semen Persicae 4-10 Flos Carthami 3-10 Rhizoma Chuanxiong 3-10
Radix Paeoniae Rubra 6-12 Radix Angelicae Sinensis 4-10 Radix Rehmanniae 9-15
Poria 9-15 Radix Astragali 9-30 Radix Angelicae Dahuricae 3-10
Radix Glycyrrhizae 1-9
2,, it is characterized in that optimum weight (part) proportioning of described each Chinese medicine is according to the Chinese medicine composition of the described treatment hemorrhagic contusion and laceration of brain of claim 1:
Semen Persicae 10 Flos Carthamis 10 Rhizoma Chuanxiongs 10
Radix Paeoniae Rubra 12 Radix Angelicae Sinensis 10 Radix Rehmanniae 12
Poria 12 Radixs Astragali 12 Radixs Angelicae Dahuricae 10
Radix Glycyrrhizae 5
3, the Chinese medicine composition of treatment hemorrhagic contusion and laceration of brain according to claim 1 and 2 is characterized in that, its medicament is any peroral dosage form that can prepare on pharmaceutics.
4, the medicine of treatment hemorrhagic contusion and laceration of brain according to claim 3 is characterized in that, its dosage form comprises mixture, granule and oral liquid.
CNB2004100408233A 2004-10-09 2004-10-09 Chinese medicinal composition for treating hemorrhagic brain contusion and laceration Expired - Fee Related CN100446791C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2004100408233A CN100446791C (en) 2004-10-09 2004-10-09 Chinese medicinal composition for treating hemorrhagic brain contusion and laceration

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100408233A CN100446791C (en) 2004-10-09 2004-10-09 Chinese medicinal composition for treating hemorrhagic brain contusion and laceration

Publications (2)

Publication Number Publication Date
CN1634249A true CN1634249A (en) 2005-07-06
CN100446791C CN100446791C (en) 2008-12-31

Family

ID=34845869

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100408233A Expired - Fee Related CN100446791C (en) 2004-10-09 2004-10-09 Chinese medicinal composition for treating hemorrhagic brain contusion and laceration

Country Status (1)

Country Link
CN (1) CN100446791C (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740195A (en) * 2015-03-03 2015-07-01 马文金 Traditional Chinese medicinal styptic powder
CN105832871A (en) * 2016-04-28 2016-08-10 刘瑞英 Traditional Chinese medicine for treating cerebral contusion and laceration

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1125107A (en) * 1994-12-22 1996-06-26 蒋争鸣 Naoyujing medicine for curing traumatic intracranial hematoma

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104740195A (en) * 2015-03-03 2015-07-01 马文金 Traditional Chinese medicinal styptic powder
CN104740195B (en) * 2015-03-03 2018-01-30 马文金 A kind of Chinese medicine hemostatic powder
CN105832871A (en) * 2016-04-28 2016-08-10 刘瑞英 Traditional Chinese medicine for treating cerebral contusion and laceration

Also Published As

Publication number Publication date
CN100446791C (en) 2008-12-31

Similar Documents

Publication Publication Date Title
WO2007009291A1 (en) A pharmaceutical composition of traditional chineses medicine for treating rheumatoid arthritis and preparation thereof
CN1304039C (en) Chinese medicine composition with functions of reducing blood-pressure, reducing-fat, anti-dizzy and calming wind, its preparing method and use
CN1813868A (en) Composition for treating and improving chronic fatigue syndrome and its preparing method
CN1052163C (en) Chinese patent medicine for curing gallstones and kidney stones
CN1927331A (en) Chinese medicine preparation for curing chronic heart failure
CN1121867C (en) Medicine for preventing and treating abortion
CN1618441A (en) Medicinal composition for regulating blood fat, prepn. method and use thereof
CN1973878A (en) Medicine for treating children's stomachache and its prepn
CN1634249A (en) Chinese medicinal composition for treating hemorrhagic brain contusion and laceration
CN1634548A (en) Medicine composition for treating viral hepatitis and its preparation method
EP3782635A1 (en) Traditional chinese medicine composition for treating cardiovascular and cerebrovascular disease, preparation method therefor and use thereof
CN1168488C (en) Chinese medicinal preparation for treating pyretic stranguria
CN1853688A (en) Chinese medicinal preparation for treating heart cerebrovascular disease and ischemic apoplexia and making method thereof
CN1712055A (en) Chinese medicinal preparation (litholytic capsule) for treating urinific calculus
CN1045890C (en) Hepatitis capsule and its prepn. technique
CN1190228C (en) Angong hemostatics
CN1232283C (en) Chinese drugs for treatment of coronary heart disease and angina pectoris
CN1682954A (en) Chinese medicine preparation for treating prostatic hyperplasia
CN1742783A (en) Natural medicine preparatino for tonifying Qi strengthening body resistance and preparing method
CN1541691A (en) Acute icterohepatitis treating Chinese traditional medicine and its preparation
CN1220510C (en) Chinese patent medicine with the functions of replenishing qi and blood and nourishing the heart to calm the mind, its preparation method and quality control method
CN1233416C (en) Compound pepsin powder for treating child dyspepsia and its preparation method
CN1250278C (en) Oral medicine for treating dementia and feeblemindedpess
CN1261156C (en) Medicine for treating chronic gastroenteritis and colitis
CN1562216A (en) Preparation of Chinese traditional medicine for curing cardiovascular and cerebrovascular disease and preparation method

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
ASS Succession or assignment of patent right

Owner name: SHANXI JINHUA HUIXING PHARMACY CO., LTD.

Effective date: 20141027

C41 Transfer of patent application or patent right or utility model
C53 Correction of patent of invention or patent application
CB03 Change of inventor or designer information

Inventor after: Wang Xianrong

Inventor after: Hong Duolun

Inventor after: Feng Hua

Inventor after: Zhu Gang

Inventor after: Gao Qian

Inventor after: Yu Haiyong

Inventor before: Wang Xianrong

Inventor before: Hong Duolun

Inventor before: Feng Hua

Inventor before: Zhu Gang

COR Change of bibliographic data

Free format text: CORRECT: INVENTOR; FROM: WANG XIANRONG HONG DUOLUN FENG HUA ZHU GANG TO: WANG XIANRONG HONG DUOLUN FENG HUA ZHU GANG GAO QIAN YU HAIYONG

TR01 Transfer of patent right

Effective date of registration: 20141027

Address after: 400038 Chongqing city gaotanyan Southwest Hospital

Patentee after: THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL University PLA

Patentee after: SHANXI JINHUA HUIXING PHARMACY Co.,Ltd.

Address before: 400038 Chongqing city gaotanyan Southwest Hospital

Patentee before: THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL University PLA

TR01 Transfer of patent right

Effective date of registration: 20210723

Address after: 400038 Chongqing Shapingba gaotanyan Southwest Hospital

Patentee after: THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL University PLA

Address before: 400038 Chongqing city gaotanyan Southwest Hospital

Patentee before: THE FIRST AFFILIATED HOSPITAL, THIRD MILITARY MEDICAL University PLA

Patentee before: SHANXI JINHUA HUIXING PHARMACY Co.,Ltd.

TR01 Transfer of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081231

Termination date: 20211009

CF01 Termination of patent right due to non-payment of annual fee